A5036460015- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Bladder and Urothelial Cancer Treatments
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Estrogen and related hormone effects
- Urinary and Genital Oncology Studies
- Urinary Bladder and Prostate Research
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Chemokine receptors and signaling
- Urologic and reproductive health conditions
- Sexual Differentiation and Disorders
- Immunotherapy and Immune Responses
- Pharmacology and Obesity Treatment
- Pelvic floor disorders treatments
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Medical Imaging and Pathology Studies
- Sexual function and dysfunction studies
- Epigenetics and DNA Methylation
Kanazawa University
2016-2025
Kanazawa University Hospital
2006-2024
Uwajima City Hospital
2023-2024
Fukui-ken Saiseikai Hospital
2021
Hirosaki University
2020
Sasaki Institute
2020
National Natural Science Foundation of China
2020
Muroran Institute of Technology
2020
Jiangsu Cancer Hospital
2019
Nanjing Medical University
2019
Prostate cancer (CaP) forms osteoblastic skeletal metastases with an underlying osteoclastic component. However, the importance of osteoclastogenesis in development CaP lesions is unknown. In present study, we demonstrate that cells directly induce from osteoclast precursors absence stroma vitro. produced a soluble form receptor activator NF-κB ligand (RANKL), which accounted for CaP-mediated osteoclastogenesis. To evaluate on tumor vivo, were injected both intratibially and subcutaneously...
Article13 January 2022Open Access Source DataTransparent process Inhibition of NPC1L1 disrupts adaptive responses drug-tolerant persister cells to chemotherapy Zhe Zhang orcid.org/0000-0001-7509-6965 Laboratory Aging Research and Cancer Drug Target, State Key Biotherapy Center, National Clinical Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, School Basic Medical Sciences & Forensic Medicine, Collaborative Innovation Biotherapy, Contribution: Conceptualization, Data...
We investigated the immunohistochemical localization of androgen receptor (AR) using a polyclonal antibody for 55 KD recombinant human AR in tissues fixed with 4% paraformaldehyde solution and embedded paraffin. Immunoreactive was restricted to nuclei various tissues. Among well-known target organs, secretory cells basal prostate, spermatogonia, spermatocytes, Sertoli Leydig testis, epithelial rete fibroblasts whole organ, squamous cells, sweat gland hair follicle skin, hepatocytes liver...
Androgen receptor (AR) is a hormone-activated transcriptional factor that can bind to androgen response elements and regulates the transcription of target genes via mechanism presumably involves cofactors. We report here cloning novel AR coactivator ARA55 using yeast two-hybrid system. consists 444 amino acids with predicted molecular mass 55 kDa its sequence shows very high homology mouse hic5, TGF-β1-inducible gene. Yeast mammalian systems co-immunoprecipitation assays all prove in...
Diminished expression of Raf kinase inhibitor protein (RKIP), an the signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model, suggesting that it is suppressor gene. However, prognostic significance RKIP and its association with PCa patients unknown.To investigate marker we performed immunohistochemical staining for tissue microarrays consisting 758 non-neoplastic tissues, primary tumors metastases from 134 patients. The Cox proportional-hazards model was used to adjust...
Abstract Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from androgen-dependent androgen-independent phenotype. One of the mechanisms relapse is antiandrogen withdrawal phenomenon caused by mutation 877th amino acid receptor (AR). In present study, we established a method measure concentration androstenediol (adiol) in tissue. We found that adiol maintains high PCa tissue even after therapy. Furthermore, stronger activator mutant AR...
Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies inhibit prostate metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We others have previously shown that blocking receptor activator of nuclear factor-kappaB ligand (RANKL) partially blocks tumor establishment progression bone murine models. However, levels RANKL the cell lines used these studies were very low, suggesting soluble factors other...
Abstract Prostate cancer (PCa) is frequently accompanied by osteosclerotic (i.e., excessive bone production) metastases. Although morphogenetic proteins (BMP) and Wnts are mediators of PCa-induced osteoblastic activity, the relation between them in PCa metastases unknown. The goal this study was to define relationship. Wnt3a Wnt5a administration or knockdown DKK-1, a Wnt inhibitor, induced BMP-4 6 expression promoter activation cells. DKK-1 blocked BMP promoters. Transfection C4-2B cells...
Purpose. We performed a randomised controlled study regarding the effects of androgen replacement therapy (ART) on lower urinary tract symptoms (LUTS) in hypogonadal men with benign prostate hypertrophy (BPH).
Previous studies have found that tumor-associated macrophages (TAMs) promote cancer progression. We previously reported TAMs prostate metastasis via activation of the CCL2-CCR2 axis. The CCR4 (receptor CCL17 and CCL22) expression level in breast was to be associated with lung metastasis. aim this study elucidate role CCR2 were expressed human cell lines tissues. In vitro co-culture cells resulted increased CCL2 levels cells. addition induced CCL22 production migration invasion enhanced...
Prostate cancer is the most common malignancy and second leading cause of cancer-related deaths in men. One treatment androgen-deprivation therapy, which reduces symptoms patients. However, over time, patients develop tumors that are androgen-independent ultimately fatal. The mechanisms this transition remain largely unknown, as a result, there no effective treatments against prostate cancer. As model platform, we used LNCaP cell line its derivative, LNCaP-SF. Utilizing stable isotope...
Abstract Human prostate cancer has a high predisposition to metastasize bone, resulting in the formation of osteoblastic metastases. The mechanism through which cells promote lesions is undefined. Vascular endothelial growth factor (VEGF) been implicated as mediator osteoblast activity. In present study, we examined if activity VEGF. We found that LNCaP and C4-2B cell lines primary tumor metastatic tissues from patients expressed Bone morphogenetic proteins (BMPs), are normally bone...
Abstract BACKGROUND Although paclitaxel is used for hormone‐resistant prostate cancer, relapse definitely occurs later. Details of the molecular mechanism responsible paclitaxel‐ resistance remain unclear. METHODS We established paclitaxel‐resistant cells, DU145‐TxR and PC‐3‐TxR from parent DU145 PC‐3. To characterize these we examined cross‐resistance to other anticancer drugs. Expression several potential genes that had been related drug‐resistance was compared with cells by RT‐PCR Western...
Abstract BACKGROUND Cyclooxygenase (COX) ‐2, an inducible isoform of COX, has been observed to be expressed in prostate cancer. Several studies have reported that COX‐2 overexpression is associated with carcinogenesis, cell growth, angiogenesis, apoptosis, and invasiveness a variety tumor types. METHODS To investigate the function cancer directly, we stably transfected human full‐length cDNA into LNCaP cells (LNCaP‐COX‐2), which express low levels endogenous COX‐2. RESULTS The level mRNA...